Bactoblis®

Protecting from ear & throat infections

winner NIA

Key marketing aspects

  • targeting the most common infections in children
  • clinically tested in children and adults -
    7 clinical trials published confirming

    • less ear and throat infections
    • less antibiotic use
  • containing the world‘s first patented oral probiotic
    for activity against Streptococcal infections
    (EP 1169340)
  • also available with vitamin D
  • high acceptance in children
  • pharmacy exclusive

Facts

  • contains the most significant human oral probiotic species1
  • effectively colonizes the oro- and nasopharynx2 
  • produces 2 types of lantibiotics that inhibit ear- and throat pathogens
    (e.g., Streptococcus pyogenes and pneumoniae)3
  • reduces the incidence of acute otitis media,
    pharyngitis & tonsilitis4, 5, 6, 8, 9, 10
  • reduces the incidence of common viral infections8
  • reduces the symtoms of secretory otitis
  • reduces the use of antibiotics6

How to use

  • for children (3+ years) and adults
  • once a day
  • during the winter season
  • after antibiotic treatment
  • when experiencing recurrent ear- and throat infections
  • when attending day care / school

References

  1. Wescombe et al., Future Microbiol (2009)
  2. Horz et al., Oral Microbiol Immunol (2007); Internal Report
  3. Hyink et al., Appl Environ Micro (2007)
  4. Di Pierro et al., Int J Gen Med (2012)
  5. Di Pierro et al., Expert Opin Biol Ther (2013)
  6. Di Pierro et al., Drug Health Care & Patient Saf (2014)
  7. Di Pierro et al., Int J Gen Med (2015)
  8. Di Pierro et al., Drug Health Care & Patient Saf (2016)
  9. Gregori et al., Ther Clin Risk Manag (2016)
  10. Di Pierro et al., Eur Rev Med Pharmacol Sci (2016)

Bactoblis® is a registered and licensed tradmark by BLUESTONE PHARMA GmbH
BLIS® is registered trademark of BLIS Technologies Ltd.